Anda di halaman 1dari 10

We will become the world's most valued company to patients, customers, colleagues, investors, business partners, and the

communities where we work and live. -Pfizer Mission Statement

Pfizer Inc. (PFE)


PRESENTERS NAME BBAD 363 Business Finance Capital Investment Analysis Presentation
Current market price: $24.04 Volume: 31,378,505

Pfizer Inc. Company History


Founded in 1849 by cousins Charles Pfizer and Charles Erhart. By 1880, the company was Americas leading producer of citric acid, an ingredient found in drinks such as Coca Cola and Pepsi. By 1906, Pfizers sales exceeded $3 million. In 1942 the company went public with 240,000 shares of common stock. By 1944, Pfizer was the worlds largest mass-producer of penicillin, using the technology of deep-tank fermentation.

Pfizer Inc. Company History


In 1951, Pfizer expanded internationally, creating operations in Belgium, Brazil, Canada, Cuba, England, Mexico, Panama, and Puerto Rico. Named the worlds most admired pharmaceutical company in 1997 by Fortune Magazine. In 1999, Pfizer was named Company of the Year by Forbes Magazine. In 2004, the company was selected by Dow Jones and Company to be included in the Dow Jones Industrial Average.

Pfizer Inc.
Company Structure Key Products
Aricept Caduet Celebrex Chantix Detrol/LA Effexor Enbrel Lipitor Lyrica Norvasc Spiriva Viagra Xalatan/Xalacom Zoloft Zyvox

Chairman of the Board & CEO: Ian Read CFO & Executive VP - Business Operations: Frank DAmelio President of Worldwide R&D: Mikael Dolsten Executive VP, Chief Compliance & Risk Officer: Douglas Lankler Executive VP Worldwide Human Resources: Charles Hill Executive VP, CMO: Freda Lewis-Hall Executive VP Worldwide Business Development & Innovation: Kristin Peck

Company Location

Corporate Headquarters: 235 East 42Nd Street New York, NY 10017

Pfizer Inc. Liquidity Ratios


Current Ratio
2.5 0.7 0.6 2 0.5 1.5

Acid-Test Ratio

0.4

0.3

0.2 0.5 0.1

0 2009 2010 2011

0 2009 2010 2011

The Current Ratio trend is steady, and in year 2011, Pfizer had $2.06 in current assets for every $1 in shortterm debt.

The Acid-Test trend is positive, and in year 2011, Pfizer had $0.61 in cash & accounts receivable per $1 in current debt.

Pfizer Inc. Operating Profitability Ratios


Total Asset Turnover
0.4 0.35 0.3 2 2.5

Inventory Turnover

0.25
0.2 0.15 0.1

1.5

0.5 0.05 0 2009 2010 2011

0 2009 2010 2011

The Total Asset trend is positive, and in 2011, Pfizer generated $0.36 in sales per dollar of assets.

The Inventory Turnover trend is steady, and in 2011, Pfizer moved its inventory 1.94 times.

Pfizer Inc. Asset Financing Ratios


Debt Ratio
24% 23% 23% 0.7 22% 22% 21% 21% 0.2 20% 20% 2009 2010 2011 0.1 0 2009 2010 2011 0.6 0.5 0.4 0.3 1 0.9 0.8

Times Interest Earned

The Debt Ratio trend is positive, and in 2011, Pfizer financed 21% of its assets with debt.

Pfizer Inc. reported no interest expense for 2009-2011. Therefore interest expense does not affect operating profits.

Pfizer Inc. ROE & Market-Value Ratios


Return on Equity
14% 17.20

Price/Earnings Ratio

12%

17.00

10%

16.80

8%

16.60

6%

16.40

4%

16.20

2%

16.00

0% 2009 2010 2011

15.80 2009 2010 2011

The Return on Equity trend is positive, and in 2011, Pfizers shareholders received 12% returns on their investments.

The Price/Earnings trend is negative, and in 2011, Pfizers investors were willing to pay $16.33 for $1 of reported earnings.

New Product: Epiregen


Epiregen is a pharmaceutical breakthrough product, which activates the essential genes required for regeneration in mammalian patients. This drug allows mammals to regenerate cells through the use of epigenetic medicine.
With proper dosage and use, patients will be able to regenerate tissues (and thereby organs and limbs) back to their pre-existing state.

New Product: Epiregen


NPV = $161,042,056.14 IRR = 476% PI = 75.69 PV of FCF = $158,942,056.14 Payback Period = Less than one year. According to the previous data, Epiregen is an excellent investment opportunity.